Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

152
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
08/25/2014 08/26/2014 08/27/2014 08/28/2014 08/29/2014 Date
81.7(c) 82.2(c) 82.3(c) 82(c) 82.35(c) Last
2 300 894 3 384 137 4 075 181 4 062 123 3 972 272 Volume
+0.43% +0.61% +0.12% -0.36% +0.43% Change
More quotes
Company
Novartis AG manufactures and markets health care and nutritional products. It provides innovative healthcare solutions and offers innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The company... 
Sector
Pharmaceuticals
Calendar
08/31 | 11:00amSpecial Situation
Surperformance© rating of Novartis AG
Trading Rating : Investor Rating :
More about the company
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 59 099 M
EBIT 2014 13 675 M
Net income 2014 10 475 M
Debt 2014 4 479 M
Yield 2014 3,04%
Sales 2015 57 805 M
EBIT 2015 14 279 M
Net income 2015 11 604 M
Debt 2015 7 605 M
Yield 2015 3,24%
PER 2014 21,20
PER 2015 19,84
EV / Sales 2014 4,20x
EV / Sales 2015 4,34x
Capitalization 243 531 M
More Financials
Latest news on NOVARTIS AG
5h ago NOVARTIS' : investigational heart failure medicine LCZ696 cut cardiovascular dea..
9h ago NOVARTIS' : new heart failure medicine LCZ696 cut cardiovascular deaths by 20% v..
9h ago NOVARTIS : Study: Novel heart failure drug shows big promise
9h ago NOVARTIS : First-of-a-kind Novartis heart failure drug saves lives, cuts hospita..
9h ago NOVARTIS' : new heart failure medicine LCZ696 cut cardiovascular deaths by 20% v..
1d ago UNITED THERAPEUTICS : rises on drug-patent ruling
1d ago NOVARTIS : Oxford Biomedica announces interim results for the six months ended 3..
2d ago NOVARTIS : announces that Xolair® is approved in Canada as a licensed therapy fo..
2d ago OXFORD BIOMEDICA : Narrows Half-Year Loss As Revenue Grows
2d ago NOVARTIS : experts and future scientific leaders meet at International BioCamp 2..
2d ago NOVARTIS : Patent Issued for Use of Immunosuppressant Compounds in a New Indicat..
2d ago NOVARTIS' : Trademark Application for "VOLTAFLEX" Filed
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
Novartis AG : Income Statement Evolution
More Financials
EPS Revisions
Novartis AG : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF